As WHO warns the antibiotics pipeline does not address the threat of bacterial resistance, the EU must step up and do more to galvanise R&D, accelerate innovation and help shape a coordinated global response to the impending crisis
The University of Amsterdam (UvA)’s Faculty of Science, UvA Ventures Holding B.V. and Innovation Exchange Amsterdam (IXA-UvA) are pooling their resources to fund Macrobian Biotech BV, a single asset biotech company that will further develop medicine for the treatment of Parkinson’s disease.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.